Effective treatment of tumors and cancer with triciribine and related compounds

1. A method for identifying and treating a patient having a tumor or cancer cell with enhanced sensitivity to triciribine (TCN) comprising:

(a) determining whether a patient has a tumor or cancer cell with enhanced sensitivity to triciribine comprising:

(i)obtaining a biological sample of the tumor or cancer cell from the patient;

(ii)measuring the expression level of Akt kinase from the tumor or cancer cell from the patient; and

(iii) comparing the expression level of Akt kinase from the tumor or cancer cell to the expression level in a control tissue,

(b) administering to the patient having a tumor or cancer cell with enhanced sensitivity to triciribine at least one compound of the formula:

wherein each R 2 ′, R 3 ′, and R 5 ′ are independently hydrogen, optionally substituted phosphate or phosphonate; acyl; alkyl; amide; solfonate ester; sulfonyl; phenyl, wherein the phenyl group is optionally substituted with one or more substituents selected from the group consisting of halo, hydroxyl, amino, alkylamino, arylamino, alkoxy, aryloxy, nitro, cyano, sulfonic acid, sulfate, phosphonic acid, phosphate, and phosphonate; optionally substituted arylsulfonyl; a phospholipid; an amino acid; a carbohydrate; a peptide; or cholesterol; or other pharmaceutically acceptable leaving group that, in vivo, provides a compound wherein R 2 ′, R 3 ′ or R 5 ′ is independently H or mono-, di- or tri-phosphate;

wherein R x and R y are independently hydrogen, optionally substituted phosphate; acyl; amide, alkyl; aromatic, polyoxyalkylene, optionally substituted arylsulfonyl; a phospholipid; an amino acid; a carbohydrate; a peptide; or cholesterol; or other pharmaceutically acceptable leaving group; and

R 1 and R 2 each are independently H, optionally substituted straight chained, branched or cyclic alkyl, alkenyl, or alkynyl, CO-alkyl, CO-alkenyl, CO-alkynyl, CO-aryl or heteroaryl, CO-alkoxyalkyl, CO-aryloxyalkyl, CO-substituted aryl, sulfonyl, alkylsulfonyl, arylsulfonyl, or aralkylsulfonyl,

wherein said treatment comprises administering 45 mg/m 2 or less of at least one compound by intravenous infusion to cause regression of the tumor or cancer cell.

2. The method of claim 1 , wherein the biological sample is taken from breast, pancreas, ovary, colon, or rectum.

3. The method of claim 1 , wherein a 1.5 fold greater expression of Akt in the tumor or cancer cell compared to a control tissue is indicative of a patient having a tumor or cancer cell with enhanced sensitivity to triciribine.

4. The method of claim 1 ,wherein the level of Akt kinase expression is determined by assaying the cancer for the presence of a phosphorylated Akt kinase.

5. The method of claim 1 ,wherein the level of Akt kinase expression is determined by assaying the cancer for the presence of a phosphorylated Akt kinase with an antibody.

6. A method of treating a tumor or cancer in a patient, wherein the tumor or cancer is of the pancreas, ovary or colon, and wherein the tumor or cancer has enhanced sensitivity to triciribine (TCN) comprising:

administering to the patient at least one compound of the formula:

wherein each R 2 ′,R 3 ′, and R 5 ′ are independently hydrogen, optionally substituted phosphate or phosphonate; acyl; alkyl; amide; sulfonate ester; sulfonyl; phenyl, wherein the phenyl group is optionally substituted with one or more substituents selected from the group consisting of halo, hydroxyl, amino, alkylamino, arylamino, alkoxy, aryloxy, nitro, cyano, sulfonic acid, sulfate, phosphonic acid, phosphate, and phosphonate; optionally substituted arylsulfonyl; a phospholipid; an amino acid; a carbohydrate; a peptide; or cholesterol; or other pharmaceutically acceptable leaving group that, in vivo, provides a compound wherein R 2 ′, R 3 ′, and R 5 ′ is independently H or mono-, di- or tri-phosphate;

wherein R x and R y are independently hydrogen, optionally substituted phosphate; acyl; amide, alkyl; aromatic, polyoxyalkylene optionally substituted arylsulfonyl; a phospholipid; an amino acid; carbohydrate; a peptide; or cholesterol; or other pharmaceutically acceptable leaving group;

R 1 and R 2 each are independently H, optionally substituted straight chained, branched or cyclic alkyl, alkenyl, or alkynyl, CO-alkenyl, CO-alkynyl, CO-alkyl or heteroaryl,CO-alkoxyalkyl, CO-aryloxyalkyl, CO-substitued aryl, sulfonyl, alkylsulfonyl, arylsulfonyl, or aralkylsulfonyl; and

wherein 45 mg/m 2 or less of the compound administered by intravenous infusion.

7. The method of claim 6 , wherein the dosing schedule is repeated at least twice.

8. The method of claim 6 , wherein the dosing schedule is repeated at least 4 times.

9. The method of claim 6 , wherein at least 10 gm/m 2 of the compound is administered.

10. The method of claim 6 , wherein 10 mg/m 2 or less of the compound is administered.

11. A method for identifying and treating a patient having a tumor or cancer cell with enhanced sensitivity to triciribine (TCN), wherein the tumor or cancer is of the pancreas, ovary or colon, comprising:

(a) determining whether a patient has a tumor or cancer cell with enhanced sensitivity to triciribine comprising:

(i) obtaining a biological sample of the tumor or cancer cell from the patient;

(ii) measuring the expression level of Akt kinase from the tumor or cancer cell from the patient; and

(iii) comparing the expression level of Akt kinase from the tumor or cancer cell to the expression level in a control tissue,

wherein a 1.5 fold greater expression of Akt in the tumor or cancer cell compared to a control tissue is indicative of patient having a tumor or cancer cell with enhanced sensitivity to triciribine; and

(b) administering to the patient at least one compound selected from the group consisting of

wherein each R 2 ′, R 3 ′, and R 5 ′ are independently hydrogen, optionally substituted phosphate or phosphonate; acyl; alkyl; amide; sulfonate ester; sulfonyl; phenyl, wherein the phenyl group is optionally substituted with one or more substituents selected from the group consisting of halo, hydroxyl, amino, alkylamino, arylamino, alkoxy, aryloxy, nitro, cyano,sulfonic acid, sulfate, phosphonic acid, phosphate, and phosphonate; optionally substituted arylsolfonyl; a phospholipid; an amino acid; a carbohydrate; a peptide; or cholesterol; or other pharmaceutically acceptable leaving group that, in vivo, provides a compound wherein R 2 ′,R 3 ′, and R 5 ′ is independently H or mono-, di- or tri-phosphate;

wherein R x and R y are independently hydrogen, optionally substituted phosphate; acyl; amide, alkyl; aromatic, polyoxyalkylene optionally substituted arylsulfonyl; a phospholipid; an amino acid; a carbohydrate; a peptide; or cholesterol; or other pharmaceutically acceptable leaving group;

R 1 and R 2 each are independently H, optionally substituted straight chained, branched or cyclic alkyl, alkenyl, or alkynyl, CO-alkyl, CO-alkenyl, CO-alkynyl, CO-aryl or heteroaryl, CO-alkoxyalkyl, CO-aryloxyalkyl, CO-substituted aryl, sulfonyl, alkylsulfonyl, arylsulfonyl, or aralkylsulfonyl; and

wherein 45 mg/m 2 or less of the compound is administered over a one-hour intravenous infusion with a dosing regimen of one time per week for three weeks.

12. The method of claim 11 , wherein the dosing cycle is repeated at least twice.

13. The method of claim 11 , wherein the dosing cycle is repeated until regression of the cancer is achieved.

14. The method of claim 11 , wherein the subject has been diagnosed with cardinoma, sarcoma, lymphoma, eukemia, or myeloma.

15. The method of claim 11 , wherein the patient is mammal.

16. The method of claim 11 , wherein the compound is the compound of Formula IB:

17. The method of claim 11 , wherein the compound is the compound of Formula IIA: